These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21654615)

  • 1. [Selective estrogen receptor modulators: focus on bazedoxifene].
    Lello S
    Minerva Ginecol; 2011 Jun; 63(3):305-14. PubMed ID: 21654615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
    Palacios S
    Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis.
    Genant HK
    Menopause Int; 2011 Jun; 17(2):44-9. PubMed ID: 21693498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis.
    Kung AW; Chu EY; Xu L
    Expert Opin Pharmacother; 2009 Jun; 10(8):1377-85. PubMed ID: 19445558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic agents for disorders of bone and calcium metabolism: Bazedoxifene].
    Chaki O
    Clin Calcium; 2007 Jan; 17(1):30-5. PubMed ID: 17211091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
    Pickar JH; Mirkin S
    Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-selective estrogen complexes for postmenopausal women.
    Mirkin S; Komm BS
    Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
    Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA
    J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bazedoxifene as a new-generation SERM].
    Ohta H
    Clin Calcium; 2011 Jan; 21(1):34-42. PubMed ID: 21187592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of SERMs for treatment in postmenopausal women.
    Pinkerton JV; Thomas S
    J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bazedoxifene acetate: a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
    Chines AA; Komm BS
    Drugs Today (Barc); 2009 Jul; 45(7):507-20. PubMed ID: 19834628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis.
    de Villiers TJ
    Climacteric; 2010 Jun; 13(3):210-8. PubMed ID: 20184423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
    Hart W; Netelenbos JC
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1771-6. PubMed ID: 10494328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
    Bachmann G; Crosby U; Feldman RA; Ronkin S; Constantine GD
    Menopause; 2011 May; 18(5):508-14. PubMed ID: 21289525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selective estrogen receptor modulators (SERMs)].
    Chaki O
    Nihon Rinsho; 2015 Oct; 73(10):1673-81. PubMed ID: 26529929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution of selective estrogen receptor modulators in osteoporosis therapy.
    Hadji P
    Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes.
    Smith CL; Santen RJ; Komm B; Mirkin S
    Breast Cancer Res; 2014 Jun; 16(3):212. PubMed ID: 25928299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.